In This Section

Continuing Medical Education

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement

AACR has designated this internet live activity for a maximum of 33.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Monday, November 22, 2021. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Request for Credit Survey

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 33.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Printable List of CME-Designated Sessions

Statement of Educational Need, Target Audience, and Learning Objectives

Molecularly targeted therapies have achieved great success from the “early days” of selective estrogen receptor modulators and aromatase inhibitors to more recent developments in signal transduction, histone deacetylases, and proteasome inhibitors. However, for each of these success stories, new challenges arise in terms of resistance, further refinement of these “targeted therapies” based on molecular sub-classification, and the opportunity to develop new combination therapies, especially with new immunotherapies. 

Targeted cancer therapeutics allow practicing clinicians to tailor cancer treatment, especially when a target is present in some but not all tumors of a particular type. Some researchers are focusing efforts on the unique set of molecular targets produced by the patient’s tumor, regardless of disease site. Targeted cancer therapies also hold the promise of being more selective for cancer cells than normal cells, thus harming fewer normal cells, reducing side effects, and improving quality of life.

Attendees at this program will be presented with the latest research in the areas of antibody drug conjugates, CAR T therapies, combination and novel trial designs, DNA damage, HER2 therapies, protein degraders, radiopharmaceuticals, and synthetic lethality, among others will be presented during the conference. The 2021 program will once again encompass basic and translational cancer research advances that have clinical implications for patients and the clinicians delivering care.

After participating in this CME activity, physicians should be able to:

  1. Analyze recent progress made in the discovery and development of molecular glues and the potential of protein degradation for therapeutic intervention.
  2. Articulate the impact of metabolism and the tumor microbiome on targeted therapeutics.
  3. Explain the advantages and disadvantages of T cell engagers and next generation CAR-T therapeutics.
  4. Identify recent developments made in the design of antibody drug conjugates and peptide-drug conjugates and their potential application for patient care.
  5. Provide an overview of novel clinical trial designs, including recent examples, and how future trial designs may increase effectiveness and impact.

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available on the website of this conference.

Planner and Speaker Financial Disclosure Index

Acknowledgment of Financial or Other Support

The AACR gratefully acknowledges the following commercial supporters:





Questions about CME?

2021 Molecular Targets and Cancer Therapeutics Conference FAQs

Please contact the Office of CME at (215) 440-9300 or [email protected].